Profile: Achaogen, Inc. develops small molecule therapeutics to treat multi-drug resistant bacterial infections. Our ACHN-490 is used in the research & nonclinical studies against systemic infections caused by multi-drug resistant gram-negative bacteria and MRSA. We also develop antibiotics that inhibit outer membrane biosynthesis via a previously unexploited target. Our LpxC agents have a novel mechanism of action, and are potent against a broad spectrum of MDR gram-negative bacteria with no pre-existing clinical resistance. We also develop compounds that inhibit targets in the bacterial SOS pathway.